Navigation Links
Dyadic International Reports 2011 First Quarter Financial Results
Date:5/5/2011

ximately $4.2 million.

About DyadicDyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries.

Dyadic makes financial disclosures through the OTC Disclosure and News Service which offers free information on the OTC Markets website (www.otcmarkets.com) concerning companies traded on the OTC Markets. Investors can access and download Dyadic's financial reports and other announcements that Dyadic makes through the OTC Markets website. Dyadic will also continue providing updates through regular press releases as appropriate.

Cautionary Statement for Forward-Looking StatementsCertain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSThree Months Ended March 31,20112010Revenue: (Unaudited) (Unaudited) Product Related Revenue, Net

$

1,805,208

$

1,879,145License Fee Revenue-32,000Research and Development Revenue491,30988,235Total Revenue2,296,5171,999,380Cost of Goods Sold1,528,2271,605,324Gross Profit768,290394,055Expenses:General and Administrative1,684,6901,359,667Sales and Marketing 267,734226,733Research and Development 304,003286,042Foreign Currency Exchange Losses (Gains), Net(94,034)33,294Total Expenses2,162,3
'/>"/>

SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Two New U.S. Patents Issued to Dyadic International
2. Dyadic International to Announce 2010 Year-End Financial Results and Hold Conference Call on March 10, 2011
3. Sixth U.S. Patent Issued to Dyadic International
4. Dyadic International and EnGen Bio to Present at Rodman & Renshaw Annual Global Investment Conference
5. Dyadic International Raises Additional $1 Million to Complete $4 Million Convertible Note Offering
6. Dyadic International Reports 2010 Second Quarter Financial Results
7. Bacterin International Holdings Launches Third Biologic Scaffold
8. INC Research to Acquire Kendle International for $15.25 per Share in Cash
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Baird Growth Stock Conference
10. Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 13th International Myeloma Workshop
11. International Leaders in Electrophysiology Discuss Improving Atrial Fibrillation Treatment Using Novel Endoscopically Guided Laser Ablation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... INCLINE VILLAGE, Nev., May 6, 2015 PDL BioPharma, ... results for the first quarter ended March 31, 2015. ... 2015 increased nine percent to $149.7 million from $136.8 ... the quarter ended March 31, 2015 included $127.8 million ... the Queen et al. patents, $11.4 million in net ...
(Date:5/6/2015)... Delcath Systems, Inc. (NASDAQ: DCTH ), ... oncology with an emphasis on the treatment of primary ... three months ended March 31, 2015.  ... , Achieved quarterly product revenue of $0.44 million, ... first quarter of 2014; , Activated a prospective ...
(Date:5/6/2015)... , May 6, 2015  Integrative medicine interventions ... patient-reported outcomes for chronic pain, depression, and stress, ... by The Bravewell Collaborative . The findings ... Receiving Integrative Medicine Interventions Effectiveness Registry (PRIMIER), the ... Using data from PRIMIER , researchers found ...
Breaking Medicine Technology:PDL BioPharma Announces First Quarter 2015 Financial Results 2PDL BioPharma Announces First Quarter 2015 Financial Results 3PDL BioPharma Announces First Quarter 2015 Financial Results 4PDL BioPharma Announces First Quarter 2015 Financial Results 5PDL BioPharma Announces First Quarter 2015 Financial Results 6PDL BioPharma Announces First Quarter 2015 Financial Results 7Delcath Reports 2015 First Quarter Financial Results 2Delcath Reports 2015 First Quarter Financial Results 3Delcath Reports 2015 First Quarter Financial Results 4Delcath Reports 2015 First Quarter Financial Results 5Delcath Reports 2015 First Quarter Financial Results 6Delcath Reports 2015 First Quarter Financial Results 7Delcath Reports 2015 First Quarter Financial Results 8Integrative Medicine has Positive Impact on Patient Activation, Chronic Pain, Depression 2
... 11, 2011 ViroPharma Incorporated (Nasdaq: ... that Halozyme has granted ViroPharma an exclusive worldwide ... proprietary drug delivery platform using Halozyme,s recombinant human ... C1 esterase inhibitor. Additionally, Halozyme has agreed not to ...
... MELVILLE, N.Y., May 11, 2011 Henry Schein, Inc. (NASDAQ: ... products and services to office-based dental, medical and veterinary practitioners, ... 500 ranking of America,s Largest Corporations.  Henry Schein,s net ... has steadily climbed the Fortune 500 rankings over the past ...
Cached Medicine Technology:ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor 2ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor 3ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor 4ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor 5ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor 6ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor 7Henry Schein Ranks #317 in 2011 Fortune 500 Ranking of America's Largest Corporations 2
(Date:5/6/2015)... 06, 2015 Baptist Medical Center ... first in north Florida and southeast Georgia region ... latest innovation in total hip replacement surgery performed ... robotic arm that enables the accurate alignment and ... has offered MAKOplasty® partial knee resurfacing using the ...
(Date:5/6/2015)... TMG Health, the leading national provider ... Medicare Part D and Managed Medicaid markets, was one ... category at the BCI North America Awards, a program ... outstanding contribution of business continuity professionals and organizations living ... the USA and Canada. The North America Awards were ...
(Date:5/6/2015)... “ SideChef ” was featured on NewsWatch as part of its ... applications on the market for iOS, Android, and Windows. Joe Toohey, ... and shared with viewers how this application walks users through recipes. ... good navigator people had to know how to read a map? ... navigator. Well what if people could “GPS” their way through a ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Marketing ... #1 ranked international water, sanitation and hygiene nonprofit by ... communities across the world and it brings our agency ... CEO of Marketing Maven. “The ongoing relationship between ... available for people to learn about and support the ...
(Date:5/6/2015)... 06, 2015 Anitha Nallari, MD ... Oncology Consultants, Inc. in Columbus, OH. Dr. Nallari will ... special focus in breast cancer, lung cancer, GI and gallbladder ... well as benign hematology. , Dr. Anitha Nallari ... by the American Board of Internal Medicine. She completed her ...
Breaking Medicine News(10 mins):Health News:Baptist Health and Jacksonville Orthopaedic Institute Offering MAKOplasty® Total Hip Replacement 2Health News:Baptist Health and Jacksonville Orthopaedic Institute Offering MAKOplasty® Total Hip Replacement 3Health News:Baptist Health and Jacksonville Orthopaedic Institute Offering MAKOplasty® Total Hip Replacement 4Health News:TMG Health Recognized by the Business Continuity Institute 2Health News:TMG Health Recognized by the Business Continuity Institute 3Health News:An Application to Guide Users through Recipes Was Featured on NewsWatch Television 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 3Health News:New Oncologist to Join Hematology Oncology Consultants, Inc. 2Health News:New Oncologist to Join Hematology Oncology Consultants, Inc. 3
... The University of North Carolina at Chapel Hill School ... Robert Wood Johnson Foundation (RWJF) to explore how interactive ... health. , UNC joins 11 other research teams supported ... Research, an RWJF national program established to strengthen the ...
... whet men,s sexual appetite. But stimulating new research in ... meets the eye. A recent study shows that men ... gratificationeven when they were making decisions about money, soda, ... DeWitte, and Luk Warlop (KULeuven, Belgium) found that the ...
... to Rally Residents to Eat Right, Move More ... and Milk Their Diets, KANSAS ... and downs of different fad diets -- which seem to go in and ... out of three Americans -- including 23 percent of Kansas City,residents -- remain ...
... finds 13.7 million without coverage, mostly because of cost , , ... adults without health insurance rose again in 2006, so 38 ... graduates will spend some time uninsured in the year after ... since 2003, and every year we,ve done the study, the ...
... Completed, WASHINGTON, May 30 The Department of,Veterans ... to,veterans potentially identified as being ill or injured from ... begin targeting over 500,000 OEF-OIF veterans who have been,discharged ... health care., "We promised to reach out to ...
... 30 On June 5th at the annual ... vote for the,second year on a shareowner proposal ... The resolution received 42% last year., Walden ... on,integrating environmental, social and governance factors into the,investment ...
Cached Medicine News:Health News:UNC health researchers explore how to take interactive video games to the next level 2Health News:UNC health researchers explore how to take interactive video games to the next level 3Health News:Message to Kansas City, MO Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Kansas City, MO Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:More Young People Going Without Health Insurance 2Health News:More Young People Going Without Health Insurance 3Health News:VA Begins Next Phase of Combat Vet Outreach 2
Reusable Components Compatible with VERSASTEP™ Reposable Access System....
The VersaStep™ 5 mm and VersaStep™ PLUS Reposable system components for creating each access port are supplied in separate packages....
... Long Instrument for applications in ... Plus Long Instrument with 150mm ... endoscopic entry device that has ... is used to establish entry ...
... Step™ and Mini Step™ device components are supplied ... Single Use System is supplied sterile in 2/3, ... in various configurations and combinations. They are used ... needle and the Step™ radially Expandable Sleeve. The ...
Medicine Products: